XtalPi Leverages AWS to Enhance Drug Discovery

Go back to XtalPi Leverages AWS to Enhance Drug Discovery

BofA on Amazon.com (AMZN): 'Remain constructive on AWS revenue acceleration in '25'

December 4, 2024 9:33 AM EST

BofA Securities analyst Justin Post reiterated a Buy rating and $230.00 price target on Amazon.com (NASDAQ: AMZN).

The analyst comments "Remain constructive on AWS revenue acceleration in '25. We see potential for AWS revenue acceleration in '25 from greater Nvidia & Tranium2 availability for... More